Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 11/20 | 0.46 |
| ▸ | AVPR2 | P30518 | 10/20 | 0.42 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5626277 | 0.91 | AVPR1A (0.48) | AVPR1AAVPR2FFAR2HSD11B1HTR2B | |
| SCHEMBL5626377 | 0.90 | AVPR1A (0.46) | AVPR1AAVPR2FFAR2HSD11B1HTR2B | |
| SCHEMBL5629020 | 0.90 | AVPR1A (0.48) | AVPR1AAVPR2HSD11B1HTR2BSLC6A7 | |
| SCHEMBL5626382 | 0.89 | AVPR1A (0.46) | AVPR1AAVPR2FFAR2HSD11B1HTR2B | |
| SCHEMBL5626621 | 0.88 | AVPR1A (0.49) | AVPR1AAVPR2 | |
| SCHEMBL5626281 | 0.87 | AVPR1A (0.46) | AVPR1AAVPR2HTR2B | |
| SCHEMBL5626431 | 0.85 | AVPR1A (0.48) | AVPR1AAVPR2HSD11B1HTR2BSLC6A7 | |
| SCHEMBL5628972 | 0.85 | AVPR2 (0.48) | AVPR1AAVPR2HSD11B1HTR2BSLC6A7 | |
| SCHEMBL5628220 | 0.84 | AVPR1A (0.43) | AVPR1AAVPR2HSD11B1HTR2B | |
| SCHEMBL5627472 | 0.84 | AVPR1A (0.46) | AVPR1AAVPR2FFAR2HSD11B1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202239-B2 | Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1377582-A1 | NOVEL 3-C(O)R SUBSTITUTED 10-CYCLOHEXYLBENZOYL PYRROLOBENZODIAZEPINES; TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Wyeth (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20030027815-A1 | Novel cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH | 2003-02-06 | — | — | US | disclosed |
| WO-2002085907-A1 | NOVEL 3-C(O)R SUBSTITUTED 10-CYCLOHEXYLBENZOYL PYRROLOBENZODIAZEPINES; TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027815-A1 | Novel cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists | OXTR, OPRL1, CRHR2 | AVPR1A 41/4885AVPR2 49/4885FFAR2 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.